Please ensure Javascript is enabled for purposes of website accessibility

Why Sorrento Therapeutics Stock Is Sinking Again Today

By Keith Speights - May 20, 2020 at 11:21AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Euphoria over the biotech's announcement last week continues to fade.

What happened

Shares of Sorrento Therapeutics (SRNE -3.30%) were sinking 11.5% lower as of 11:34 a.m. EDT on Wednesday. There weren't any new developments to cause Sorrento's shares to fall. Instead, it appears that investors continued to think that the stock's huge gain following the drugmaker's announcement last week of promising preclinical results for an experimental COVID-19 antibody might have been too much too soon.

So what

Extreme volatility is par for the course with small biotech stocks like Sorrento. Good news gets investors all excited. Then that excitement often fades to some extent as they fully digest the news.

Gloved hands holding two test tubes

Image source: Getty Images.

In Sorrento's case, the main issue is that its good news was really early. The company found an antibody (STI-1499) that demonstrated the ability to completely neutralize the novel coronavirus that causes COVID-19. However, this result came from a lab study of the antibody and the virus in a test tube. It's not uncommon at all for promising in vitro results to fail to translate to success in clinical testing in humans. 

Sorrento's STI-1499 antibody could turn out to be tremendously effective at fighting COVID-19 and have an attractive safety profile. But it's still way too soon to know if that will be the case. Investors seem to be recognizing that reality.

Now what

Keep your eyes on Sorrento's progress in advancing ST-1499 to an early-stage clinical trial. The company stated that it "plans to request priority evaluation and accelerated review from regulators," but it has to gain approval to begin a phase 1 clinical study first. If results are positive in a phase 1 study, there will be a good reason for investors to regain their excitement.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
$2.05 (-3.30%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.